Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma
Details
Publication Year 2024-07,Volume 99,Issue #7,Page 1281-1289
Journal Title
American Journal of Hematology
Publication Type
Research article
Abstract
The Phase 2 portion of this study evaluated safety and efficacy of polatuzumab vedotin 1.8 mg/kg and venetoclax 800 mg, plus fixed-dose obinutuzumab 1000 mg or rituximab 375 mg/m(2) in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), respectively. Patients with complete response (CR) or partial response (PR)/stable disease (FL) or CR/PR (DLBCL) at end of induction (EOI; six 21-day cycles) received post-induction therapy with venetoclax and obinutuzumab or rituximab, respectively. Primary endpoint was CR rate at EOI. Safety-evaluable populations included 74 patients (FL cohort; median age 64 years; progression of disease within 24 months on first-line treatment, 25.7%; FL International Prognostic Index 3-5, 54.1%; ≥2 previous therapies, 74.3%) and 57 patients (DLBCL cohort; median age 65 years; International Prognostic Index 3-5, 54.4%; ≥2 previous therapies, 77.2%). The most common non-hematologic adverse events (mostly Grades 1-2) in the FL and DLBCL cohorts were diarrhea (55.4% and 47.4%, respectively) and nausea (47.3% and 36.8%); neutropenia was the most common Grades 3-4 toxicity (39.2% and 52.6%). Efficacy-evaluable populations included patients treated at the recommended Phase 2 dose (FL, n = 49; DLBCL, n = 48). CR rates at EOI were 59.2% (FL) and 31.3% (DLBCL); median progression-free survival was 22.8 months (95% confidence interval [CI], 14.5-not evaluable) and 4.6 months (95% CI, 3.6-8.1), respectively. Polatuzumab vedotin plus venetoclax and obinutuzumab/rituximab had acceptable safety in patients with R/R FL or DLBCL, with promising response rates in R/R FL, including high-risk patients.
Publisher
Wiley
Keywords
Humans; Middle Aged; Aged; Male; *Sulfonamides/administration & dosage/therapeutic use/adverse effects; Female; *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse; effects/administration & dosage; *Bridged Bicyclo Compounds, Heterocyclic/therapeutic use/administration &; dosage/adverse effects; *Lymphoma, Large B-Cell, Diffuse/drug therapy; *Antibodies, Monoclonal, Humanized/therapeutic use/administration &; dosage/adverse effects; Adult; Aged, 80 and over; *Rituximab/administration & dosage/therapeutic use/adverse effects; Lymphoma, Follicular/drug therapy; Antibodies, Monoclonal/therapeutic use/administration & dosage/adverse effects; Recurrence; Immunoconjugates
Department(s)
Clinical Haematology
Open Access at Publisher's Site
https://doi.org/10.1002/ajh.27341
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-08-27 07:14:46
Last Modified: 2024-08-27 07:28:18

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙